{
    "title": "Regeneron's Eylea drug sales hit by competition from 'new kid in town'",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12046267/Regeneron-beats-quarterly-profit-estimates-Dupixent-strength.html",
    "date": "2023-05-04",
    "keywords": [
        "eylea",
        "regeneron",
        "approval",
        "drug",
        "version",
        "roy",
        "competition",
        "companys",
        "analyst",
        "company",
        "dupixent",
        "blockbuster",
        "eye",
        "street",
        "thursday",
        "trade",
        "bayer",
        "ag",
        "growth",
        "driver",
        "rival",
        "year",
        "bit",
        "kind",
        "effect",
        "hutton",
        "michael",
        "vabysmo",
        "try",
        "market",
        "feature",
        "defense",
        "place",
        "emphasis",
        "need",
        "execution",
        "launch",
        "capital",
        "seigerman",
        "note",
        "refinitiv",
        "share",
        "revenue",
        "ceo",
        "leonard",
        "schleifer",
        "health",
        "decision",
        "june",
        "treatment",
        "asthma",
        "atopic",
        "dermatitis",
        "partner",
        "sanofi",
        "profit",
        "beat",
        "collaboration",
        "raghav",
        "mahobe",
        "bengaluru",
        "editing",
        "syamnath"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}